March 1, 2024 Issue of JAMA Oncology

March 2024, Vol 10, No. 3, Pages 286-416

Original Investigation

Mirtazapine as Appetite Stimulant in Patients With Non鈥揝mall Cell Lung Cancer and Anorexia: A Randomized Clinical Trial

Oscar Arrieta, MD, MSc; Daniela Cárdenas-Fernández, BSD; Oscar Rodriguez-Mayoral, MD; et al.

Abstract Full Text

JAMA Oncol. 2024;10(3):305-314. doi:10.1001/jamaoncol.2023.5232

This randomized clinical trial assesses the effect of mirtazapine on appetite and energy consumption in patients with advanced non鈥搒mall cell lung cancer (NSCLC).

Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non鈥揝mall Cell Lung Cancer: A Phase 3 Randomized Clinical Trial

Yoshimasa Shiraishi, MD; Junji Kishimoto, MA; Shunichi Sugawara, MD, PhD; et al.

Abstract Full Text

JAMA Oncol. 2024;10(3):315-324. doi:10.1001/jamaoncol.2023.5258

This randomized clinical trial compares progression-free survival using treatment with atezolizumab plus carboplatin with pemetrexed vs atezolizumab, carboplatin with pemetrexed, and bevacizumab in patients with non鈥搒mall cell lung cancer.

Whole-Brain Radiotherapy Alone vs Preceded by Bevacizumab, Etoposide, and Cisplatin for Untreated Brain Metastases From Breast Cancer: A Randomized Clinical Trial

Tom Wei-Wu Chen, MD, PhD; Ming-Shen Dai, MD, PhD; Ling-Ming Tseng, MD, PhD; et al.

Abstract Full Text

JAMA Oncol. 2024;10(3):325-334. doi:10.1001/jamaoncol.2023.5456

This randomized clinical trial investigates whether induction bevacizumab, cisplatin, and etoposide improves brain-specific progression-free survival after whole-brain radiotherapy in patients with brain metastases from breast cancer.

Brain Radiotherapy With Pyrotinib and Capecitabine in Patients With ERBB2-Positive Advanced Breast Cancer and Brain Metastases: A Nonrandomized Phase 2 Trial

Zhaozhi Yang, MD, PhD; Jin Meng, MD, PhD; Xin Mei, MD, PhD; et al.

Abstract Full Text

JAMA Oncol. 2024;10(3):335-341. doi:10.1001/jamaoncol.2023.5791

This nonrandomized trial examines the activity and safety of combining radiotherapy with pyrotinib and capecitabine in patients with ERBB2-positive breast cancer and brain metastases.

Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US

Daniel M. Kerekes, MD, MHS; Alexander E. Frey, MD; Elizabeth H. Prsic, MD; et al.

Abstract Full Text

has audio

JAMA Oncol. 2024;10(3):342-351. doi:10.1001/jamaoncol.2023.6025

This cohort study describes patient characteristics, practice patterns, and risk factors concerning end-of-life鈥搃nitiated immunotherapy over time in patients with metastatic cancer in the US.

Podcast: Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US

Editorial
Initiating Immunotherapy in the Treatment of Stage IV Cancers in the Month Before Death鈥擜 Health Care Disparities Lens
Michael Hoerger, PhD, MSCR, MBA; Navya Nair, MD, MPH; Sonia Malhotra, MD, MS

JAMA Oncol

Accelerated Hypofractionated Chemoradiation Followed by Stereotactic Ablative Radiotherapy Boost for Locally Advanced, Unresectable Non鈥揝mall Cell Lung Cancer: A Nonrandomized Controlled Trial

Trudy C. Wu, MD; Elaine Luterstein, MD; Beth K. Neilsen, MD, PhD; et al.

Abstract Full Text

JAMA Oncol. 2024;10(3):352-359. doi:10.1001/jamaoncol.2023.6033

This nonrandomized controlled trial aims to determine the maximum tolerated dose and use of hypofractionated concurrent chemoradiation with an adaptive stereotactic ablative radiotherapy boost for patients with locally advanced, unresectable non鈥搒mall cell lung cancer (NSCLC).

Invited Commentary
Stereotactic Body Radiotherapy in Locally Advanced Non鈥揝mall Cell Lung Cancer鈥擨s This the Future?
Nataniel H. Lester-Coll, MD; Henry S. Park, MD, MPH

JAMA Oncol

Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor鈥揜ich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial

Cynthia X. Ma, MD, PhD; Vera J. Suman, PhD; Souzan Sanati, MD; et al.

Abstract Full Text

open access

JAMA Oncol. 2024;10(3):362-371. doi:10.1001/jamaoncol.2023.6038

This randomized clinical trial assesses whether neoadjuvant fulvestrant or anastrozole plus fulvestrant vs anastrozole alone increases endocrine-sensitive disease rate (ESDR) in postmenopausal women with estrogen receptor (ER)鈥搑ich/ERBB2-negative breast cancer.

Investigation of Genetic Alterations Associated With Interval Breast Cancer

Juan Rodriguez, PhD; Felix Grassmann, PhD; Qingyang Xiao, PhD; et al.

Abstract Full Text

open access

JAMA Oncol. 2024;10(3):372-379. doi:10.1001/jamaoncol.2023.6287

This genetic association study examines whether rare germline deleterious protein-truncating variants can be applied to discriminate between interval cancer and screen-detected cancer while considering mammographic density in women with breast cancer.

Brief Report

Review of Racial and Ethnic Representation of Participants Enrolled in Pediatric Clinical Trials of Oncology Drugs Conducted Through FDA Written Requests

Lola A. Fashoyin-Aje, MD, MPH; Alemayehu Y. Akalu, PharmD; Jessica Boehmer, MBA; et al.

Abstract Full Text

JAMA Oncol. 2024;10(3):380-383. doi:10.1001/jamaoncol.2023.5781

This review examines the race and ethnicity of participants enrolled in pediatric studies conducted in response to written requests from the US Food and Drug Administration (FDA) for which pediatric exclusivity was granted between 2001 and 2021.

Substance Use Disorders Among US Adult Cancer Survivors

Katie F. Jones, PhD; Oyomoare L. Osazuwa-Peters, PhD; Andrea Des Marais, MPH; et al.

Abstract Full Text

JAMA Oncol. 2024;10(3):384-389. doi:10.1001/jamaoncol.2023.5785

This cross-sectional study examines the prevalence of substance use disorder according to type of cancer among adult US cancer survivors.

Out-of-Pocket Costs and Outpatient Visits Among Patients With Cancer in High-Deductible Health Plans

Nicolas K. Trad, MD; Fang Zhang, PhD; James Franklin Wharam, MD, MPH

Abstract Full Text

JAMA Oncol. 2024;10(3):390-394. doi:10.1001/jamaoncol.2023.6052

This cohort study examines out-of-pocket health care costs and outpatient visits in patients with cancer who switched from low-deductible to high-deductible health care plans.

Research Letter

Efficacy of Tixagevimab-Cilgavimab as Immunoprophylaxis in Patients With Hematologic Cancer

Marco Salvini, MD; Paolo Antonio Grossi, MD, PhD; Alessandro Cacioppo, MD; et al.

Abstract Full Text

JAMA Oncol. 2024;10(3):405-407. doi:10.1001/jamaoncol.2023.6446

This cohort study compares outcomes for patients with hematologic malignant tumors who prophylactically received tixagevimab-cilgavimab against SARS-CoV-2 with those who did not.

Review

Critical Appraisal of Guideline Recommendations on Systemic Therapies for Advanced Hepatocellular Carcinoma: A Review

Sarah Cappuyns, MD; Virginia Corbett, MD; Mark Yarchoan, MD; et al.

Abstract Full Text

has active quiz

JAMA Oncol. 2024;10(3):395-404. doi:10.1001/jamaoncol.2023.2677

This narrative review compares the clinical benefit and safety profile of the recommended first-line and second-line drug regimens for advanced hepatocellular carcinoma.

Viewpoint

The Case for Allowing Proton Beam Therapy on Head and Neck Cooperative Group Studies

Neal S. McCall, MD; Steven J. Frank, MD; William A. Stokes, MD

Abstract Full Text

JAMA Oncol. 2024;10(3):289-290. doi:10.1001/jamaoncol.2023.6274

This Viewpoint present the case for revisiting the proscription of proton beam therapy in trials of patients with de novo, nonmetastatic head and neck cancer.

Examining Medicaid Waivers鈥擜n Opportunity to Promote Equity in Cancer Care

Lily J. Greene, BA; Benjamin Carter, PhD; Andrew P. Loehrer, MD, MPH

Abstract Full Text

JAMA Oncol. 2024;10(3):291-292. doi:10.1001/jamaoncol.2023.6814

This Viewpoint discusses the impact of Medicaid Section 1115 waivers on the equity of cancer care delivery in the US.

Editorial

Initiating Immunotherapy in the Treatment of Stage IV Cancers in the Month Before Death鈥擜 Health Care Disparities Lens

Michael Hoerger, PhD, MSCR, MBA; Navya Nair, MD, MPH; Sonia Malhotra, MD, MS

Abstract Full Text

JAMA Oncol. 2024;10(3):297-299. doi:10.1001/jamaoncol.2023.5932

Invited Commentary

Stereotactic Body Radiotherapy in Locally Advanced Non鈥揝mall Cell Lung Cancer鈥擨s This the Future?

Nataniel H. Lester-Coll, MD; Henry S. Park, MD, MPH

Abstract Full Text

JAMA Oncol. 2024;10(3):360-361. doi:10.1001/jamaoncol.2023.5856

JAMA Oncology Patient Page

Clinical Trials for Patients With Cancer

Fawzi Abu Rous, MD; Aakash Desai, MD, MPH; Eric K. Singhi, MD

Abstract Full Text

free access

JAMA Oncol. 2024;10(3):416. doi:10.1001/jamaoncol.2023.5778

This JAMA Oncology Patient Page explains clinical trials and what patients should consider regarding enrollment.

Cancer Care Chronicles

Thinking That I Had Cancer Made Me a Better Oncologist

Mary McGunigal, MD

Abstract Full Text

JAMA Oncol. 2024;10(3):293-294. doi:10.1001/jamaoncol.2023.4834

This essay describes the author鈥檚 experience with a cancer scare and the increased empathy and experience gained.

The Wrong Fight鈥擯rior Authorization

Arman A. Shahriar, MD

Abstract Full Text

JAMA Oncol. 2024;10(3):295-296. doi:10.1001/jamaoncol.2023.5801

This essay describes the author鈥檚 experience with denial of prior authorization for imaging to complete cancer staging.

Poetry and Oncology

Somebody Else鈥檚 Palms

Danielle Chammas, MD

Abstract Full Text

JAMA Oncol. 2024;10(3):414. doi:10.1001/jamaoncol.2023.5804

Comment & Response

Wildfire Exposure and Lung Cancer Survival

Akihiko Ozaki, MD, DrPH; Michio Murakami, PhD; Claire Leppold, PhD

Abstract Full Text

JAMA Oncol. 2024;10(3):407-408. doi:10.1001/jamaoncol.2023.6123

Wildfire Exposure and Lung Cancer Survival鈥擱eply

Leticia M. Nogueira, PhD, MPH; Yang Liu, PhD

Abstract Full Text

JAMA Oncol. 2024;10(3):408-409. doi:10.1001/jamaoncol.2023.6126

HIMALAYA Overall Survival Prominence and Other Routes to the Peak

Ghassan K. Abou-Alfa, MD, MBA; Bruno Sangro, MD, PhD

Abstract Full Text

JAMA Oncol. 2024;10(3):409. doi:10.1001/jamaoncol.2023.6268

HIMALAYA Overall Survival Prominence and Other Routes to the Peak鈥擱eply

Josep M. Llovet, MD, PhD; Sarah Cappuyns, MD, PhD; Richard S. Finn, MD

Abstract Full Text

JAMA Oncol. 2024;10(3):409-410. doi:10.1001/jamaoncol.2023.6271

Unveiling an Overlooked Link鈥擯romising Drug Efficacy in Lowering Withdrawal Rates in Cancer Trials

Michioki Endo, MD; Akihiko Ozaki, MD, DrPH; Masahiro Kami, MD, PhD

Abstract Full Text

JAMA Oncol. 2024;10(3):410-411. doi:10.1001/jamaoncol.2023.6434

Unveiling an Overlooked Link鈥擯romising Drug Efficacy in Lowering Withdrawal Rates in Cancer Trials鈥擱eply

Shauna L. Hillman, MS; Aminah Jatoi, MD; Sumithra J. Mandrekar, PhD

Abstract Full Text

JAMA Oncol. 2024;10(3):411. doi:10.1001/jamaoncol.2023.6437

Correction

Errors in the Abstract, Table 1, Text, and Reference List

Abstract Full Text

free access

JAMA Oncol. 2024;10(3):411. doi:10.1001/jamaoncol.2023.6378

Corrections to Results, Figure 2, and Table 3

Abstract Full Text

free access

JAMA Oncol. 2024;10(3):411. doi:10.1001/jamaoncol.2023.6747

Error in Text

Abstract Full Text

free access

JAMA Oncol. 2024;10(3):411. doi:10.1001/jamaoncol.2023.6760

Error in Author Affiliation

Abstract Full Text

free access

JAMA Oncol. 2024;10(3):411-412. doi:10.1001/jamaoncol.2023.7132

Error in Figure

Abstract Full Text

free access

JAMA Oncol. 2024;10(3):412. doi:10.1001/jamaoncol.2024.0049

Errors in Key Points and Abstract

Abstract Full Text

free access

JAMA Oncol. 2024;10(3):412. doi:10.1001/jamaoncol.2024.0267

October 2024 - April 2015

Decade

Year

Issue

March 2024, Vol 10, No. 3, Pages 286-416